Edesa Biotech Net Income From Continuing Ops Over Time
| EDSA Stock | USD 1.05 0.07 6.25% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Edesa Biotech Performance and Edesa Biotech Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Edesa Biotech. Projected growth potential of Edesa fundamentally drives upward valuation adjustments. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Edesa Biotech assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Edesa Biotech using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Edesa Biotech's intrinsic value - the estimated true worth - helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Edesa Biotech's market price to deviate significantly from intrinsic value.
It's important to distinguish between Edesa Biotech's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Edesa Biotech should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Edesa Biotech's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income From Continuing Ops Analysis
Compare Edesa Biotech and related stocks such as BioRestorative Therapies, Dogwood Therapeutics, and Cocrystal Pharma Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| BRTX | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (5.6 M) | (7.9 M) | (8.6 M) | (9.4 M) | (12.5 M) | (14.6 M) | (10 M) | (44.3 M) | (18.5 M) | (15.9 M) | (9 M) | (8.1 M) | (8.5 M) |
| DWTX | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (10.3 M) | (16 M) | (12.2 M) | (5.3 M) | (12.3 M) | (14.2 M) | (14.9 M) |
| COCP | (11.6 M) | (11.6 M) | (11.6 M) | (11.6 M) | (203 K) | (50.1 M) | (74.9 M) | (613 K) | (49 M) | (48.2 M) | (9.6 M) | (14.2 M) | (38.8 M) | (18 M) | (17.5 M) | (20.1 M) | (21.1 M) |
| OSRH | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 1.1 M | 403.8 K | (2.4 M) | (2.2 M) | (2.1 M) |
| TRAW | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (25.2 M) | (16.2 M) | (19 M) | (18.9 M) | (166.5 M) | (149.9 M) | (142.4 M) |
| IMRN | (2.5 M) | (2.5 M) | (2.5 M) | (2.5 M) | (1.9 M) | (7.1 M) | (6.8 M) | (3 M) | (4.6 M) | (2.9 M) | (8.4 M) | (2.9 M) | (3.8 M) | (6.9 M) | (5.2 M) | (4.7 M) | (4.9 M) |
| ERNA | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (7.3 M) | (122.3 M) | (24.6 M) | (20 M) | (44.5 M) | (51.2 M) | (53.8 M) |
| EVGN | (8.9 M) | (8.9 M) | (8.9 M) | (8.9 M) | (14.5 M) | (17.2 M) | (19.6 M) | (20.8 M) | (20.8 M) | (19.1 M) | (26.2 M) | (30.4 M) | (29.8 M) | (22.4 M) | (18.1 M) | (16.2 M) | (17.1 M) |
| SNSE | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (13 M) | (16.7 M) | (20.1 M) | (36.8 M) | (48.6 M) | (38.9 M) | (30.2 M) | (27.1 M) | (28.5 M) |
| IMNN | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (11.9 M) | (16.9 M) | (21.5 M) | (20.8 M) | (35.9 M) | (27.9 M) | (18.6 M) | (16.8 M) | (17.6 M) |
Edesa Biotech and related stocks such as BioRestorative Therapies, Dogwood Therapeutics, and Cocrystal Pharma Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| Edesa Biotech | EDSA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 100 Spy Court, |
| Exchange | NASDAQ Exchange |
USD 1.05
Check out Edesa Biotech Performance and Edesa Biotech Correlation. For information on how to trade Edesa Stock refer to our How to Trade Edesa Stock guide.You can also try the Portfolio File Import module to quickly import all of your third-party portfolios from your local drive in csv format.
Edesa Biotech technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.